Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Qilu Pharma In-Licenses China Rights to Herceptin Biosimilar from Alteogen

publication date: Mar 31, 2017
Qilu Pharma of Jinan signed an agreement for China co-development and marketing of a biosimilar developed by Korea's Alteogen. The molecule, ALT-L2, is a biosimilar to Roche's Herceptin, which is used to treat breast and gastric cancers. ALT-L2 is ready to start a Phase III trial in Canada. Alteogen will transfer the technology for the drug to Qilu for China use. In February, Qilu Pharma launched a biosimilar version of AstraZeneca's Iressa in China, a treatment for non-small cell lung cancer. More details....

Stock Symbols: (SIX: ROG) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital